KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Other Non Operating Income (2017 - 2025)

Historic Other Non Operating Income for Neogenomics (NEO) over the last 9 years, with Q4 2025 value amounting to $84000.0.

  • Neogenomics' Other Non Operating Income rose 11948.96% to $84000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $296000.0, marking a year-over-year increase of 17810.03%. This contributed to the annual value of $296000.0 for FY2025, which is 17810.03% up from last year.
  • According to the latest figures from Q4 2025, Neogenomics' Other Non Operating Income is $84000.0, which was up 11948.96% from -$335000.0 recorded in Q3 2025.
  • Neogenomics' Other Non Operating Income's 5-year high stood at $730000.0 during Q2 2023, with a 5-year trough of -$4.9 million in Q1 2021.
  • In the last 5 years, Neogenomics' Other Non Operating Income had a median value of $12000.0 in 2022 and averaged -$258800.0.
  • In the last 5 years, Neogenomics' Other Non Operating Income plummeted by 227668.16% in 2021 and then surged by 2420000.0% in 2025.
  • Neogenomics' Other Non Operating Income (Quarter) stood at -$930000.0 in 2021, then skyrocketed by 99.89% to -$1000.0 in 2022, then soared by 12500.0% to $124000.0 in 2023, then tumbled by 447.58% to -$431000.0 in 2024, then soared by 119.49% to $84000.0 in 2025.
  • Its Other Non Operating Income was $84000.0 in Q4 2025, compared to -$335000.0 in Q3 2025 and $482000.0 in Q2 2025.